P ulmonary arterial hypertension (PAH) is a vascular remodeling disease (VRD) first described as an obstructive pathology affecting the distal pulmonary arteries. It is characterized by enhanced inflammation, vasoconstriction, and proliferation/apoptosis imbalance within the arterial wall, leading to increased pulmonary vascular resistance and right ventricular (RV) failure and death.
P ulmonary arterial hypertension (PAH) is a vascular remodeling disease (VRD) first described as an obstructive pathology affecting the distal pulmonary arteries. It is characterized by enhanced inflammation, vasoconstriction, and proliferation/apoptosis imbalance within the arterial wall, leading to increased pulmonary vascular resistance and right ventricular (RV) failure and death. 1 The smooth muscle cells (SMCs) within the pulmonary arterial wall exhibit exaggerated proliferation and resistance to apoptosis. Many groups have studied the underlying mechanisms of this "cancer-like" phenotype to find better ways to treat this deadly disease. The similarities in histological features between PAH and other VRDs suggest common pathogenic mechanisms. We and others have described the implication of the receptor of advanced glycation endproducts, [2] [3] [4] the oncoprotein kinase Pim-1 3, 5 and the transcription factor nuclear factor of activated T cells 6, 7 in promoting proliferation in remodeling processes occurring in both VRD and PAH. In PAH patients' lung vasculature, these molecular actors are, at least in part, regulated by proinflammatory cytokines, alterations in the miR-223/DNA damage/ Poly[ADP-ribose] polymerase 1/miR-204 axis [8] [9] [10] [11] and subsequent overexpression of the epigenetic reader bromodomain protein 4 (BRD4).
12 BRD4 functions as a scaffold for transcription factors at promoters and superenhancers, modulating the chromatin landscape and facilitating transcriptional activation of target genes. 13 Interestingly, BRD4 is also implicated in systemic VRD by triggering proinflammatory endothelial genes, such as IL-6 (interleukin-6), tumor necrosis factor-α, and monocyte chemoattractant protein-1, 14, 15 which also stimulate its activation through a feedback loop. 15 Interestingly, these proinflammatory cytokines are upregulated in PAH 16 and are known to cause DNA damage. 9 Thus, BRD4 is a key regulator of the proliferation/apoptosis balance 12, 13 by modulating gene expression and plays a critical role in post-DNA damage events. 17 In cancer, BRD4 is a known trigger of the osteogenic factor Runt-related transcription factor 2 expression, 18, 19 which was recently associated with PAH lung abnormalities (including proliferation and calcification), 20 and, interestingly, BRD4 inhibition by JQ1 suppressed vascular calcification/atherogenic processes in a hypercholesterolemic murine model. 15 Furthermore, in addition to promoting DNA damage, 17 atherogenic processes 15 and increased proliferation, 12, 13 BRD4 is also associated with inflammation, diabetes mellitus, obesity, and metabolic abnormalities, 13 all playing a role in VRDs, and particularly in coronary artery disease (CAD). 21, 22 Heart diseases are the leading global cause of death in both men and women in industrialized countries. 22 Although CAD is the most common form of heart disease, recent studies showed that coronary microvascular diseases (MVDs) are also associated with increased risk of ischemic events and heart failure. 23 The risk factors that cause CAD (diabetes mellitus, inflammatory disease, overweight, and obesity) also cause MVD and both diseases are characterized by sustained inflammation, 24 increased DNA damage 25, 26 and exaggerated proliferation within the arterial wall. 24, 27 Intriguingly, CAD is 4× more prevalent in patients with PAH compared with the general population with no underlying disease related to the coronary vasculature (28.4% versus 7.3%), 28, 29 suggesting that a link could be established between these 2 diseases. Furthermore, a recent study analyzed trends and outcomes in PAH-related hospitalization in the United States and observed an increase in associated comorbid conditions in patients with PAH between the years 2001 and 2012, such as diabetes mellitus, hypertension, and CAD. 30 During that decade, CAD in patients with PAH increased from 15.6% to 22.3%, in addition to an increase in diseases considered as risk factors for coronary diseases. This concept is not surprising because PAH is now recognized not to be restricted to the lungs. [31] [32] [33] [34] Therefore, we hypothesize that sustained activation of BRD4 during PAH will progressively contribute to coronary alterations (CAD or MVD) in these vulnerable patients. This may be attributable to detrimental conditions, such as increased inflammation, known to cause DNA damage and activate this epigenetic reader, 15, 17, 35 that propagate to the coronary arteries and activate the BRD4 axis in the heart. We propose to study whether DNA damage and inflammatory-dependent BRD4 activation in PAH may influence the development of CAD by triggering SMC proliferation and resistance to apoptosis within the coronary arterial wall.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Patients With PAH Exhibit Increased Coronary Wall Thickness, Which Is Also Present in Animal Models of the Disease
We first measured coronary arterial remodeling in heart tissues of patients with and without PAH after α-smooth muscle actin staining and demonstrated that vascular wall of coronary arteries of patients with PAH are thicker compared with the ones of controls ( Figure 1A ). Moreover, we separated our results upon the localization of the arteries within the heart and showed that there were no noteworthy differences between coronary arterial remodeling in the RV or in left ventricle ( Figure IA in the online-only Data Supplement). Thus, coronary arteries in PAH are remodeled independently of their localization within the heart. Interestingly, when investigating the clinical characteristics of our patients with PAH (Table I in the online-only Data Supplement), we observed that 23% of our patients with PAH received a diagnostic of CAD, which corresponds to what was observed in the study by Anand et al 30 and that close to half of them also exhibited risk factors for developing the disease. Furthermore, when looking at the autopsy reports, an additional 23% of the patients with PAH had CAD and these numbers do not include coronary MVDs.
We then investigated whether this increase in coronary remodeling also occurs in animal models of PAH. As shown in Figure 1B , we observed greater coronary wall thickness in the monocrotaline-induced rat model. Four weeks after monocrotaline injection, these rats have coronary arterial wall twice as thick as those from control rats ( Figure 1B) . As in humans, there is no distinction in coronary remodeling between the RV and the left ventricle ( Figure IB in the online-only Data Supplement). Using a time course, we showed that coronary remodeling parallels PAH development ( Figure IC in the online-only Data Supplement), suggesting that both pathologies are linked together. Moreover, coronary perfusion was assessed using Microfil perfusion and computed tomography scan subsequent imaging at the end of the protocol. Using this technique, we observed a decrease in coronary perfusion in monocrotaline-induced PAH rats ( Figure 1C ), which can be, at least in part, explained by the increase in coronary arterial remodeling ( Figure 1B ). To further strengthen our hypothesis, we also assessed coronary perfusion in the Sugen/hypoxiainduced PAH rat model. We found that coronary circulation was also altered in this experimental model. Sugen/hypoxiainduced PAH rats exhibited a 28% decrease in coronary perfusion ( Figure ID in the online-only Data Supplement). These data suggest that animal models of PAH also develop coronary alterations, which should be kept in mind when studying new therapeutic targets for PAH. To investigate the potential role of proinflammatory cytokines in remodeling processes occurring in coronary arteries of patients with PAH, we measured IL-6 expression in heart tissues of these patients. IL-6 mRNA levels were increased by 6-fold in heart tissues of patients with PAH, as assessed by quantitative reverse transcription-polymerase chain reaction ( Figure 1D ).
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In agreement with this, we observed an increase in IL-6 mRNA levels in heart tissues of monocrotaline-induced PAH rats, although the difference was not significant ( Figure 1E ). Because this proinflammatory environment is known to promote DNA damage in PAH patients' lungs, 9 we investigated whether the increase in IL-6 levels in the heart was associated with increased DNA damage within the coronary arteries of patients with PAH. As shown in Figure 1F , coronary arteries of patients with PAH exhibited close to 3× more DNA damage as assessed by p53-binding protein 1 immunofluorescence staining compared with controls. This phenomenon was also observed in the monocrotaline-induced PAH rats ( Figure 1G ).
BRD4 Is Overexpressed in Coronary Arteries of Patients With PAH and of Animal Models of the Disease
In addition to causing DNA damage within the arterial wall, proinflammatory cytokines are also known to trigger BRD4 expression. First, we assessed BRD4 expression and localization within heart tissues of patients with PAH. BRD4 was overexpressed in coronary arteries of patients with PAH, showed by positive BRD4 staining colocalized with smooth muscle actin staining ( Figure 2A ). BRD4 was overexpressed in coronary arterial wall in both the RV and the left ventricle ( Figure IIA in the online-only Data Supplement). We also observed a 2-fold rise in the number of BRD4-positive cells within the coronary arterial wall in the monocrotaline-PAH rats compared with The vascular wall area was divided on total vessel area (n=4 rats per group, mean of 10 arteries per ventricle per rat). C, Coronary perfusion and total heart volume were measured using the Microview software after radiopaque silicone rubber Microfil injection. Percentage of perfusion was calculated by dividing the vasculature signal volume (Microfil) on the total organ volume (n=3-5). Three-dimensional reconstruction of the organ was performed using the OsiriX software. D and E, Interleukin-6 mRNA levels were measured by quantitative reverse transcription-polymerase chain reaction in heart tissues of (D) patients with PAH (n=4) and in (E) monocrotaline (MCT)-PAH rat model (n=4). F and G, DNA damage was measured in coronary arteries of (F) patients with PAH (n=5 patients per group) and (G) in MCT-PAH rats (n=5 rats per group) by immunofluorescence detection of p53-binding protein 1 (53BP1). Nuclei appear in blue (stained with DAPI [4',6-diamidino-2-phenylindole]) and positive cells for 53BP1 (in red) were counted and reported on the total amount of cell per artery (SMA in green). *P<0.05, **P<0.01, and ****P<0.0001.
control rats ( Figure 2B ). Furthermore, using the same time course as in Figure IC in the online-only Data Supplement, we observed that BRD4 expression within the coronary arterial wall slightly increased (not significant) within the first 2 weeks after monocrotaline injection, being significantly overexpressed 3 weeks after monocrotaline injection ( Figure IIB in the online-only Data Supplement), when PAH is already established. 5 To validate our observations in PAH animal models, we also observed a 2-fold increase in the amount of BRD4-positive cells within the coronary arterial wall Sugen/hypoxiainduced PAH ( Figure IIC in the online-only Data Supplement). To strengthen our findings, we measured BRD4 expression by Western blot in isolated human coronary artery smooth muscle cells (hCoASMCs) from patients with PAH. Consistently with what we observed in human heart tissues, BRD4 expression was increased by 4-fold in PAH-hCoASMCs compared with control cells ( Figure 2C ).
Inflammation Triggers DNA Damage and BRD4 Expression Within hCoASMCs
To establish a causal link between the increased IL-6 levels and the increased DNA damage and BRD4 expression that we observed within the coronary arteries of these patients, we stimulated control hCoASMCs with IL-6 and measured the downstream effects of this proinflammatory cytokine on DNA damage and on BRD4 expression. Similarly to what we observed in human coronary arteries, cultured PAHhCoASMCs also exhibited sustained DNA damage (more than 3× more), assessed by γ-H2AX staining ( Figure 2D ). Moreover, control hCoASMCs stimulated with IL-6 (100 ng/mL for 48 hours) exhibited increased DNA damage ( Figure 2D ). IL-6 treatment in control hCoASMCs also triggered a 2-fold increase in BRD4 mRNA levels, mimicking what was observed in PAH-hCoASMCs ( Figure 2E ), suggesting that proinflammatory cytokines, such as IL-6, might contribute to BRD4 overexpression within the coronary arteries of patients with PAH.
Pathobiology Overlap Between Coronary Arteries in PAH and CAD Patients
To further investigate the role of BRD4 overexpression in coronary dysfunction, we extended our research to coronary arteries of patients with known CAD. As CAD and MVD share many features (risk factors and vascular abnormalities), we Bromodomain protein 4 (BRD4) is overexpressed within the coronary arterial wall in pulmonary arterial hypertension (PAH). A, Percent of BRD4-positive cells within the coronary arteries in heart tissues section was measured using immunofluorescence. Results are presented as mean of 10 arteries per patients in n=7 controls and 8 patients with PAH. B, The same approach was used in the monocrotaline (MCT)-PAH rats (n=6-7 rats per group). C, BRD4 protein expression was measured by immunoblot in control and PAH human coronary artery smooth muscle cells (hCoASMCs; n=3-4). Protein expression was normalized to total protein content (using Amidoblack). D, DNA damage was assessed using γ-histone H2AX (γ-H2AX) immunofluorescence staining on control hCoASMCs, stimulated or not with interleukin-6 (IL-6; 100 ng/mL for 48 hours), and on PAH-hCoASMCs (n=3). E, BRD4 levels were measured by quantitative reverse transcription-polymerase chain reaction in control hCoASMCs, with or without IL-6 stimulation (100 ng/mL for 48 hours) as well as in PAH-hCoASMCs (n=3). *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.
investigated whether proximal sections of coronary arteries of CAD and PAH patients also exhibit increased DNA damage and BRD4 expression. Using p53-binding protein 1 staining by immunochemistry, we observed a 2-fold increase in DNA damage within the coronary arteries of CAD and PAH patients, when compared with non-CAD and non-PAH controls ( Figure 3A) . Coronary arteries of patients with CAD also exhibited a 2.23-fold increase in BRD4-positive cells, as assessed by BRD4 immunofluorescence staining ( Figure 3B) . Interestingly, the increase in BRD4-positive cells was even greater in PAH proximal coronary arteries ( Figure 3B ). To further validate BRD4 overexpression within the coronary arterial wall, we isolated SMCs from proximal coronary arteries of patients with CAD and measured BRD4 expression by Western blot. We showed that BRD4 expression was 2.5× higher in CAD-hCoASMCs compared with control cells (Figure 3C ). Taken together, we showed that patients affected by PAH and CAD have increased DNA damage and exhibited BRD4 overexpression within their coronary arteries, suggesting a role for these mechanisms in coronary dysfunction regardless of the pathogenesis of the disease.
BRD4 Triggers a Proliferation/Apoptosis Imbalance Within the Coronary Arterial Wall
To study the impact of BRD4 overexpression in hCoASMCs, we measured proliferation and apoptosis in PAH-hCoASMCs and CAD-hCoASMCs treated or not with the BRD4 pharmacological inhibitor JQ1 to fully appreciate the role for BRD4 in coronary remodeling processes. Using Ki67 staining, we demonstrated that hCoASMCs isolated from PAH and CAD patients exhibited significantly higher proliferation rates when compared with control hCoASMCs ( Figure 4A ). Moreover, PAH-hCoASMCs and CAD-hCoASMCs were less prone to undergo apoptosis (Annexin V) in serum starvation conditions, as they showed a 60% and 69% decrease in apoptosis levels respectively, compared with control cells (Figure 4B ). In both PAH and CAD, the proliferation/apoptosis imbalance was reversed upon BRD4 inhibition using JQ1 treatment (1 µmol/L for 48 hours) to levels similar as those observed in control cells ( Figure 4A and 4B) . This confirms the role of the epigenetic reader BRD4 in the hyper-proliferative and apoptosis-resistant phenotype of the hCoASMCs implicated in coronary arterial remodeling processes.
IL-6 Stimulates Proliferation in a BRD4-Dependent Manner
In this study, we showed that the proinflammatory cytokine IL-6 was increased in heart tissues of patients with PAH ( Figure 1D ) and could induce DNA damage and BRD4 expression in control hCoASMCs ( Figure 2D and 2E) . We investigated the implication of increased IL-6 levels in the hyperproliferative phenotype that characterized hCoASMCs Figure 3 . DNA damage and bromodomain protein 4 (BRD4) are also increased in coronary arteries of patients with coronary artery disease (CAD). A, DNA damage was measured by p53-binding protein 1 (53BP1) immunohistochemistry in proximal coronary arteries of controls and patients with pulmonary arterial hypertension (PAH) or with CAD (n=10-11 per group). B, BRD4 expression was observed by immunofluorescence in coronary arteries from CAD and PAH patients. The percentage of cells with a positive nuclear staining for BRD4 (in red) was measured and divided by the total number of cells per artery (DAPI [4',6-diamidino-2-phenylindole]; n=10-11 per group). C, BRD4 protein expression was measured by immunoblot in control and CAD human coronary artery smooth muscle cells (hCoASMCs; n=3). Protein expression was normalized to total protein content (using Amidoblack). *P<0.05, **P<0.01 and ****P<0.0001 of patients with PAH. To do so, we mimicked the PAH condition in control CoASMC by exposing them to IL-6. We also added JQ1 to establish whether the impact the proinflammatory environment may have on proliferation was BRD4-dependent. We observed that IL-6 stimulation increased proliferation levels in control hCoASMCs by 2.5-fold and this increase was abolished upon JQ1 treatment ( Figure 5A ). Taken together, the proinflammatory environment in heart tissues of patients with PAH may stimulate DNA damage, BRD4 expression, and trigger a hyper-proliferative phenotype of the hCoASMCs, leading to vascular remodeling.
BRD4 Inhibition Shows Beneficial Effects on the Coronary Circulation
To further explore the beneficial effect of inhibiting BRD4 in PAH, we investigated the coronary circulation in heart tissues of the Sugen/hypoxia-induced PAH rat model treated with either a molecular (a silencer RNA against BRD4 [siBRD4]) or a pharmacological BRD4 inhibitor (JQ1), or their respective vehicle (scrambled siRNA or dimethyl sulfoxide) by intratracheal nebulization. These rats were used in a previous publication 12 where we measured the therapeutic potential of BRD4 inhibition on lung alterations in PAH. Nevertheless, the coronary circulation of these rats was not explored in the framework of that study. We demonstrated that the Sugen/ hypoxia-induced PAH rats, as well as the vehicle-treated rats (scrambled siRNA or dimethyl sulfoxide), had increased coronary arterial remodeling when compared with control rats (Figure 5B) , likely explaining the decrease in coronary perfusion observed in this model ( Figure ID in the online-only Data Supplement). Moreover, the coronary wall thickness was decreased by 33% and 27% in rats treated with either a molecular (siBRD4) or a pharmacological (JQ1) BRD4 inhibitor, respectively ( Figure 5B ). BRD4 inhibition was also associated with improvements in hemodynamic measurements (mean pulmonary artery pressures of 16, 54, 50, 29, 54, and 36 mm Hg for Control, Sugen-PAH, Sugen-PAH+scrambled siRNA, Sugen-PAH+siBRD4, Sugen-PAH+dimethyl sulfoxide, and Sugen-PAH+JQ1, respectively) and lung vascular remodeling. 12 We also observed that siBRD4-treated rats exhibited over 50% knockdown of BRD4-positive cells within their coronary arteries ( Figure IID in the online-only Data Supplement). This may be attributable to the decrease in IL-6 levels within heart tissues, as shown below, or through other feedback loops that still need to be investigated.
Furthermore, we studied the impact of inflammation on the coronary circulation and investigated whether improvement in PAH hemodynamics may affect coronary remodeling through a modulation of proinflammatory cytokines expression. We showed that IL-6 levels were increased in heart tissues of Sugen/hypoxia-induced PAH rats compared with control rats ( Figure 5C ). Rats in which BRD4 was inhibited, by siBRD4 or JQ1, exhibited a decrease in IL-6 mRNA levels, 5.31-and 2.14-fold respectively, compared with their respective mock-treated rats ( Figure 5C ). These results strongly support our hypothesis that the proinflammatory environment in PAH can play a role in triggering coronary arterial remodeling and potentially in the development of comorbidities in these already vulnerable patients ( Figure 6 ).
Discussion
This is the first study exploring the coronary abnormalities at the cellular and molecular level in patients with PAH. We observed that BRD4, which is increased in the lungs of patients with PAH, 12 is also overexpressed in their coronary arteries and is responsible, at least in part, for triggering vascular remodeling processes and increasing the risk of these patients to develop MVD or CAD. We showed that coronary arteries of patients with PAH, regardless of their location within the heart (RV or left ventricle), had greater wall thickness ( Figure 1A ; Figure IA in the online-only Data Supplement), exhibited increased inflammation (IL-6, Figure 1D ), sustained DNA damage ( Figure 1F) , and significantly more BRD4-expressing cells (Figure 2A ; Figure IIA in the online-only Data Supplement). These abnormalities were also present in the coronary circulation of animal models of the disease. More precisely, the monocrotaline-induced PAH rat model exhibited decreased coronary perfusion ( Figure 1C ), which is, at least in part, attributable to increased wall thickness ( Figure 1B) . Using a time course, we showed that coronary remodeling parallels PAH development ( Figure IC in the online-only Data Supplement), suggesting that both diseases may be linked together. The monocrotaline-induced PAH rats also exhibited increased DNA damage and BRD4 overexpression within the coronary arterial wall (Figures 1G and 2B) . At the cellular level, hCoASMCs from both PAH and CAD patients displayed increased proliferation levels and were resistant to serum starvation-induced apoptosis (Figure 4) . Further studies will be needed to fully understand the downstream effectors through which BRD4 induces vascular remodeling. BRD4, as an epigenetic reader, can trigger the transcription of multiple genes. Among these, signal transducer and activator of transcription 3 36 and nuclear factor of activated T cells 12 are key factors promoting cell cycle progression and proliferation. 13 We also pointed out the presence of increased DNA damage and BRD4 overexpression in proximal coronary arteries of . Results are presented as mean of 10 arteries per rat in 6 to 8 rats per group. C, IL-6 mRNA levels were assessed by quantitative reverse transcription-polymerase chain reaction in the same groups as coronary remodeling (n=4 rats per group). *P<0.05 and **P<0.01 PAH and CAD patients (Figure 3) . Thus, we showed that at both proximal and distal levels, coronary arteries of patients with PAH exhibited these vascular abnormalities, suggesting a role for these mechanisms in predisposing to coronary dysfunction (CAD or MVD) in these vulnerable patients.
The mechanisms accounting for BRD4 overexpression are likely to be multifactorial, but the proinflammatory environment seems to play an important role. Interestingly, PAH and CAD/MVD are recognized to exhibit increased inflammation, which can induce DNA damage, trigger BRD4 expression, and increase vascular remodeling. Thus, we investigated the role of the proinflammatory cytokine IL-6 because it is one of the major elevated cytokine in both PAH and CAD. 16, 37, 38 We observed an increase in IL-6 mRNA levels in heart tissues of patients with PAH, as well as in animal models of the disease (Figures 1D, 1E , and 5C). We understand that this is not specific of the coronary arteries, but this proinflammatory environment can play an important role in triggering vascular remodeling and subsequent comorbidities in these patients. Furthermore, this proinflammatory cytokine induced DNA damage and BRD4 expression in vitro in control hCoASMCs, mimicking what was observed in PAH-hCoASMCs ( Figure 2D and 2E) . Stimulation with IL-6 also triggered hCoASMC proliferation in a BRD4-dependent manner ( Figure 5A ). Taken together, the proinflammatory environment in heart tissues of patients with PAH may stimulate DNA damage, BRD4 expression, and trigger a hyper-proliferative phenotype of the hCoASMCs, leading to vascular remodeling ( Figure 6 ). BRD4 can also induce cytokine production 14, 39 and thus maintain this inflammatory environment in the coronary arteries of patients with PAH and in time, its own expression. Furthermore, although not addressed in this study, genetic alterations may also play a role in predisposing patients with PAH to coronary comorbidities, such as SNPs in BRD4 but also gene copy number variation in this gene, which has been associated with cancer. 40, 41 In this study, we also investigated whether the use of BRD4 inhibitors by intratracheal nebulization in the Sugen/ hypoxia-induced PAH rat model, which has beneficial effect on lung function, 12 could also affect the coronary circulation. This animal model, such as the monocrotaline-PAH model, exhibits increased vascular remodeling ( Figure 5B ) and increased BRD4-positive cell within the coronary arteries ( Figure IIC in the online-only Data Supplement). Figure 6 . Schematic representation. Sustained inflammation and increased cytokine levels, such as interleukin-6 (IL-6), in the heart of patients with pulmonary arterial hypertension (PAH) can lead to sustained DNA damage within the coronary arterial wall. This proinflammatory environment and increased DNA damage triggers bromodomain protein 4 (BRD4) overexpression in the coronary arterial smooth muscle cells (CoASMCs). In time, increased BRD4 expression promotes CoASMCs proliferation, prevents cell death, and thus contributes to vascular remodeling. BRD4 is also known to promote the expression of IL-6 and other proinflammatory cytokines. Clinically available BRD4 pharmacological inhibitor JQ1 was shown to restore the proliferation/apoptosis balance within these CoASMCs and prevent vascular remodeling.
Interestingly, when studying heart tissues of rats treated with BRD4 inhibitors (siBRD4 or JQ1), we found that treated rats had less coronary remodeling than their mock-treated controls ( Figure 5B ). This was associated with decreased IL-6 expression within the heart ( Figure 5C ). This effect on IL-6 levels may be attributable to decreased BRD4 expression/activation because chromatin immunoprecipitation analyses showed that BRD4 directly binds to promoter of the proinflammatory cytokines IL-6 and tumor necrosis factor-α, increasing their expression in activated macrophages in chronic inflammatory diseases, 14 thus suggesting a positive feedback loop between this inflammatory environment and BRD4 overexpression.
Our study reinforces the concept that PAH is a disease that is not restricted to the lungs. We suggest that alterations first seen in the lungs may propagate to other organs and cells; in this case to the coronary arteries favoring CAD/MVD development in PAH. We suggest that increased proinflammatory cytokines in patients with PAH 16 may trigger DNA damage in the lungs, 9 as well as in the coronary arteries, but alterations in DNA damage and DNA repair mechanisms have also been described in peripheral blood mononuclear cells of PAH patients. 31 Interestingly, Botto et al 25 showed that increased DNA damage in peripheral blood lymphocytes of patients with CAD correlated with disease severity suggesting again that PAH and CAD may share common altered signaling pathways, and this may affect the risk of patients with PAH to develop coronary abnormalities (CAD and MVD). Thus, alterations in the heart should be considered when studying PAH because many pathological processes are happening in the heart of these patients and RV failure is not strictly a consequence of pulmonary vasculature pathogenesis. 42 Studying the coronary vasculature should be included in new preclinical research to better predict patients' outcome, which is already challenging. 43 Needless to say that aside from the pathogenic SMCs, endothelial cell dysfunction also contributes to vascular remodeling processes. 44 Indeed, the endothelium is important for cardiovascular health, as it provides a protective layer, regulates vascular tone, and blood vessel growth. 44, 45 When activated by inflammation or other stimuli, endothelial cells may become dysfunctional and can alter the underlying SMCs by releasing inflammatory cytokines. 45 Interestingly, a recent article by Mumby et al 46 established the implication of BRD4 in triggering the expression of inflammatory genes (IL-6 and IL-8) in human pulmonary microvascular endothelial cells. Also, a recent study suggested that BRD4 plays a role in the atherogenic processes by regulating an inflammatory response in endothelial cells. In this study, we focused on SMCs because exaggerated proliferation and migration of the latter play a major role in neointima formation in the pulmonary circulation of patients with PAH, and this also seems to be the case in coronary abnormalities. 27 Nevertheless, this does not rule out a role for BRD4 in other cell types implicated in vascular remodeling processes. Moreover, other vasculoprotective factors are altered in PAH and CAD. A recent study showed that patients with CAD have lower circulating levels of miR-126, likely playing a role in plaque instability. 47 In PAH, miR-126 was also described as an important player of endothelial integrity and its downregulation in patients with PAH led to decreased vascular density in the RV 33 and peripheral muscle. 32 Thus, these epigenetic alterations may also increase the susceptibility of patients with PAH to develop CAD.
Although our study is in line with recent clinical evidences demonstrating CAD as a PAH comorbidity, PAH is a rare disease and in many cases CAD is not investigated in these patients. We hope that our study will generate enough intention to (1) warn clinicians on the importance of CAD in PAH. Indeed, a better clinical investigation of these patients is critical for studying exactly the impact of CAD on PAH patient's survival and quality of life for example. (2) A better identification of these patients will facilitate down the road the establishment of larger bio-bank with, for example, isolation of hCoASMCs from heart transplanted patients with PAH or warm autopsy at a much larger scale, which will allow research community to better study the mechanism of CAD in patients with PAH.
Conclusions
To our knowledge, this is the first study unveiling molecular pathways implicated in coronary arterial remodeling in patients with PAH. We and others previously provided evidence for the implication of the epigenetic reader in the pathogenic processes occurring in the pulmonary circulation of patients with PAH, but here we show that the role for BRD4 in PAH physiopathology is not restricted to the lungs. We suggest a pathobiology overlap between coronary arteries in PAH and CAD, as both exhibit increased inflammation, DNA damage, and BRD4 expression. In both diseases, BRD4 triggers a proliferation/apoptosis imbalance favoring cell survival. This study points out common mechanisms between lung vascular remodeling and coronary remodeling in these patients, making them more at risk of developing such comorbidities and rising awareness to keep this in mind when evaluating a patient or when testing new drugs in animal models of the disease. The fact that BRD inhibitors are now being clinically tested for various diseases, we hope that our work will generate enough interest to in a near future test clinically available BRDs inhibitor in PAH and CAD patients.
